Trials in Massachusetts.
98 APOE4-relevant Alzheimer’s trials run in Massachusetts — 52 of them recruiting. Each one translated into plain English, with our read on what it means for an APOE4 carrier.
- Carriers enrolled, but higher ARIA riskNCT01767311A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's Disease
This Phase 2 trial tested lecanemab, an anti-amyloid antibody given by infusion, in people with early Alzheimer's disease — either mild cognitive impairment or…
- Built exclusively for APOE 4/4 carriersNCT02565511A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
This trial tested two investigational drugs, CAD106 (a vaccine-like immunotherapy targeting amyloid) and CNP520 (a small molecule targeting amyloid…
- Built specifically for APOE4 carriersNCT03131453A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
This trial tested CNP520, a drug designed to reduce amyloid buildup in the brain, against a placebo in cognitively normal older adults at elevated risk for…
- Open to carriers, but ARIA risk elevatedNCT03887455A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
This Phase 3 trial tests lecanemab, an intravenous and subcutaneous antibody drug, against placebo in people with early Alzheimer's disease — either mild…
- Directly recruits APOE4 carriersNCT04430517Effects of Nicotinamide Riboside on Bioenergetics and Oxidative Stress in Mild Cognitive Impairment/Alzheimer's Dementia
This early-phase trial is testing nicotinamide riboside, a form of vitamin B3, in people who already have mild cognitive impairment or mild Alzheimer's…
- APOE4 carriers explicitly welcomedNCT04468659AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
This Phase 3 trial is testing lecanemab, an anti-amyloid antibody drug, in people who are cognitively normal but have early amyloid buildup in their brains —…
- Built exclusively for APOE4/4 carriersNCT04770220An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects
This Phase 3 trial is testing ALZ-801, an oral drug designed to reduce toxic amyloid clusters in the brain, against a placebo in people with early Alzheimer's…
- Requires at least one APOE4 alleleNCT05245903Passive Sensor Identification of Digital Biomarkers to Assess Effects of Orally Administered Nicotinamide Riboside
This trial is testing whether a supplement called nicotinamide riboside (a form of vitamin B3) produces measurable changes in brain energy metabolism in people…
- APOE4/4 only, closed to new enrolleesNCT06304883Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects
This is a long-term extension of a Phase 3 trial testing ALZ-801, an oral drug designed to reduce toxic amyloid clumps in the brain. Researchers are tracking…
- General AD trial, no APOE4 focusNCT00265148Brain Imaging Study Of Rosiglitazone Efficacy And Safety In Alzheimer's Disease
This Phase 2 trial tested rosiglitazone, a drug originally developed for type 2 diabetes, against a placebo in people with mild to moderate Alzheimer's…
- APOE4 enrolled, response may differNCT00348140Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease
This Phase 3 trial tested rosiglitazone, a diabetes drug, as an add-on to standard Alzheimer's medications like Aricept in people with mild to moderate…
- Amyloid-focused, drug did not succeedNCT02008357Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
This Phase 3 trial tested solanezumab, an antibody drug given by IV infusion, in cognitively normal older adults who already had amyloid buildup in their…
- Open to carriers, not 4-specificNCT02245737An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
This trial tested lanabecestat, a BACE inhibitor drug designed to reduce amyloid production in the brain, against a placebo over two years in people with early…
- Imaging study, genotype not consideredNCT02649985PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases
This Phase 1 study uses specialized PET brain scans to look for microglial activation — a sign of brain inflammation — in people with multiple sclerosis and…
- Discontinued trial, not APOE4-specificNCT02972658A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia
This Phase 3 trial tested lanabecestat, a BACE inhibitor drug designed to reduce amyloid production in the brain, in people with early Alzheimer's dementia. It…
- Unrelated to APOE4 or Alzheimer'sNCT02994719Gait Analysis in Neurological Disease
This study is analyzing how people with Parkinson's disease and related movement disorders walk at different speeds. Researchers want to identify gait patterns…
- Unrelated to APOE4 or Alzheimer'sNCT03047369The Myelin Disorders Biorepository Project
This is a biorepository project, not a treatment trial. Researchers are collecting medical records and biological samples (like blood or tissue) from people…
- Open to carriers, not 4-specificNCT03108846Escitalopram for Agitation in Alzheimer's Disease
This Phase 3 trial is testing whether escitalopram, a common antidepressant, can safely reduce agitation in people who already have Alzheimer's dementia. Phase…
- Open to carriers, not 4-specificNCT03507257Longitudinal Early-onset Alzheimer's Disease Study Protocol
LEADS is an observational study, not a treatment trial. Researchers are tracking how early-onset Alzheimer's and related conditions progress over time in…
- Open to carriers, not 4-specificNCT03556280Multi-Center Study of Sensory Stimulation to Improve Brain Function
This trial tests a device called the GammaSense Stimulation System, which delivers sensory stimulation at a specific brain rhythm frequency called gamma.…
- Lifestyle study, genotype not requiredNCT03772977The Brain Health Champion Study
This trial tests whether more frequent, personalized coaching on brain-healthy habits produces better follow-through than standard doctor advice alone.…
- Open to carriers, genotype ignoredNCT03840083Sleep-dependent Learning in Aging
This study is exploring how sleep helps the brain consolidate memories, and whether age-related memory problems are tied to changes in sleep, changes in memory…
- Not APOE4-related, movement disorder focusNCT03924414Trial of Parkinson's And Zoledronic Acid
This trial is testing whether a single IV infusion of zoledronic acid, a bone-strengthening drug already approved for osteoporosis, can reduce fractures in…
- Late-stage dementia care, not preventionNCT03926520Electroconvulsive Therapy (ECT) for Agitation in Dementia (AD)
This trial is testing whether electroconvulsive therapy (ECT) — brief, controlled electrical stimulation of the brain — can safely reduce severe agitation in…
- Open to carriers, genotype not trackedNCT04042922High Frequency Light and Sound Stimulation to Improve Brain Functions in Alzheimer's Disease
This trial tests a device that delivers flickering light and rhythmic sound at 40 Hz to stimulate brain activity in people with mild Alzheimer's disease.…
- Device trial, carriers not excludedNCT04055376Daily Light and Sound Stimulation to Improve Brain Functions in Alzheimer's Disease
This trial is testing whether daily exposure to flickering light and pulsed sound at a specific frequency (40 Hz, known as gamma stimulation) can improve brain…
- Open to carriers, genotype not trackedNCT04098666Metformin in Alzheimer's Dementia Prevention
This trial is testing whether extended-release metformin, a widely used diabetes drug, can slow memory decline in people who are overweight and already showing…
- Observational study, genotype not consideredNCT04124029Contributions of mTBI to Neurodegeneration Due to Chronic Traumatic Encephalopathy (CTE) and Alzheimer's Disease (AD)
This observational study is not testing a treatment. It is using EEG brain scans, MRIs, blood draws, and spinal fluid samples to study whether Veterans who…
- Not relevant to APOE4 carriersNCT04165109Trial-Ready Cohort-Down Syndrome (TRC-DS)
This is not a treatment trial. It is a study building a pool of adults with Down syndrome, ages 25 to 55, who are ready to be recruited into future Alzheimer's…
- Open to carriers, not 4-specificNCT04262206Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults
PREVENTABLE is a large Phase 4 trial testing whether atorvastatin 40 mg — a common cholesterol-lowering statin — can reduce the combined risk of death,…
- Open to carriers, genotype not trackedNCT04289402Individualized Brain Stimulation to Improve Mobility in Alzheimer's Disease
This pilot trial is testing whether a personalized form of transcranial direct current stimulation (tDCS) — a non-invasive technique that delivers a mild…
- FTLD-focused, not APOE4-relevantNCT04363684ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
This is a large North American research registry and natural history study tracking people with frontotemporal lobar degeneration (FTLD) and related conditions…
- Wrong condition, not APOE4-relevantNCT04408625Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)
This trial is testing LY3884963, a biological therapy delivered directly into the fluid around the brain and spine, in people who have frontotemporal dementia…
- High ARIA risk for carriersNCT04437511A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
This Phase 3 trial tested donanemab, an anti-amyloid antibody drug, against placebo in people with early Alzheimer's disease. Researchers measured how well it…
- Open to carriers, not 4-specificNCT04784416Transcranial Photobiomodulation for Alzheimer's Disease (TRAP-AD)
This trial is testing whether shining near-infrared laser light through the forehead — called transcranial photobiomodulation, or tPBM — can improve brain…
- Open to carriers, not 4-specificNCT04838301Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease
This trial is testing allopregnanolone — a naturally occurring brain steroid — to see whether it slows or improves cognition in people with mild Alzheimer's…
- Open to carriers, not 4-specificNCT04908358The Wandering Nerve: Gateway to Boost Alzheimer's Disease Related Cognitive Performance
This trial is testing a non-invasive device called RAVANS, or tVNS, which delivers a gentle electrical pulse to the ear to stimulate the vagus nerve — a major…
- Observational only, genotype not specifiedNCT04916210Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on RecoverY
The DISCOVERY study is an observational study — no drug or treatment is being tested. Researchers are following stroke survivors over time, collecting…
- Open to carriers, not 4-specificNCT05040321Sirtuin-NAD Activator in Alzheimer's Disease
This trial is testing MIB-626, an oral pill designed to boost NAD levels in the brain by activating the sirtuin-NAD pathway — a cellular energy and repair…
- Not relevant to APOE4 carriersNCT05196984Gamma Frequency Stimulation in Individuals With Down Syndrome
This trial tests a non-drug device called GENUS that delivers flickering light, sound, and vibration at a specific brain frequency called gamma. Researchers…
- Open to carriers, not 4-specificNCT05336695Assess Fibrin in Brains With AD/ADRD
This trial is testing a specialized PET/MR brain scan using a radioactive tracer called 64Cu-FBP8 to measure fibrin deposits in the brain. Fibrin is a clotting…
- Open to carriers, genotype not trackedNCT05373745Managing Pain and Cognitions in Older Adults With Early Cognitive Decline and Chronic Pain
This trial tests two behavioral programs called Active Brains 1 and Active Brains 2, both delivered over video, designed to help older adults who have both…
- Open to carriers, not 4-specificNCT05399888A Study to Learn About the Safety of BIIB080 Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age
This Phase 2 trial is testing BIIB080, a drug injected into the spinal fluid, to see whether it can slow cognitive decline in people with mild cognitive…
- Anti-amyloid drug — carriers face higher ARIA riskNCT05463731A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)
This Phase 3 trial is testing remternetug, an anti-amyloid antibody given by IV or injection under the skin, in people with early symptomatic Alzheimer's…
- Open to carriers, not 4-specificNCT05479552A Diagnostic Test for Dementia With Lewy Bodies
This study is testing a diagnostic tool called the Syn-One Test, which looks for a protein called alpha-synuclein in a skin biopsy. The goal is to better…
- Open to carriers, not 4-specificNCT05655195Chronic Treatment of Alzheimer's Disease by Gamma Light and Sound Therapy
This trial tests a home-use light and sound device that pulses at 40 Hz — a specific brain-wave frequency — to see whether daily use over six months changes…
- Open to carriers, genotype not assessedNCT05661084Non-invasive Brain Stimulation for Cognitive and Motor Dysfunction in Dementia
This trial is testing whether a caregiver-administered brain stimulation technique called transcranial electrical stimulation (tES) can improve memory,…
- Not relevant to APOE4 or Alzheimer'sNCT05686551GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease
This trial is testing tominersen, a drug injected into the spinal fluid, against a placebo in people with prodromal or early Huntington's Disease. The goal is…
- ARIA-focused — carriers often restrictedNCT05738486A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)
This Phase 3 trial is testing whether different dosing schedules of donanemab — an anti-amyloid antibody already conditionally approved — can reduce the rate…
- Huntington's only, not relevantNCT05773196Prospective Single-Timepoint Huntington's Disease Biospecimen Collection Study
This study collects blood samples from people already diagnosed with Huntington's Disease. Researchers want to validate a genetic test that measures CAG repeat…
Copy a forum-ready post
Keep exploring
Educational, not medical advice. Trial decisions belong between you and your physician.